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Simple Summary: Metastatic progression represents a major clinical challenge and remains the
leading cause of death in cancer patients. Identification of suitable therapeutic targets, followed by a
rational design of effective drug agents and their long-term, extensive pre-clinical and clinical testing
is one of the key goals in cancer research. Trophoblast cell surface antigen 2 (Trop2) was first described
as a protein highly expressed on the surface of trophoblast cells in 1981. Just recently, nearly 40 years
after this discovery, sacituzumab govitecan, a Trop2-targeting antibody drug conjugate, has been
granted an accelerated approval for therapy of metastatic triple-negative breast cancer, opening a
new chapter of such successful story. The aim of this review is to summarize the current knowledge
about Trop2 function in healthy tissue and pathology, with a special focus on its still controversial
role in plasticity and heterogeneity during cancer progression. We further discuss the development
and potential of Trop2-targeted therapy.
Abstract: Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial
cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane
protein, other subcellular localizations and processed forms were described. Its congenital mutations
cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function
in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates
with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of
different origins; however, functional studies revealed both oncogenic and tumor suppressor roles.
Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug–antibody
conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan,
has been recently granted an accelerated approval for therapy of metastatic triple-negative breast
cancer. In this article, we review the current knowledge about the yet controversial function of Trop2
in homeostasis and pathology.
Keywords: Trop2; TACSTD2; cancer; proliferation; metastases; epithelial-to-mesenchymal
transition; therapy
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1. Gene and Protein
Trophoblast cell surface antigen 2 (Trop2) was first described in 1981 as a protein highly expressed
on the surface of trophoblast cells [1]. It is also known as EGP-1, M1S1, and GA733-1 [2]. Trop2 is
encoded by the TACSTD2 (tumor-associated calcium signal transducer 2) gene, which is a member of
the TACSTD gene family [3,4]. The second member of this family, TACSTD1 (also known as EpCAM),
encodes epithelial cell adhesion molecule (EpCAM). Trop2 and EpCAM share 49% identity and 67%
similarity of amino acid sequence with highly similar distribution of hydrophilic and hydrophobic
residues [5,6]. The results of sequence analysis suggest that in the evolution of TACSTD gene family
exon shuffling occurred, since some exons of TACSTD genes are homologous to exons of genes coding
for thyroglobulin, HLA-DR-associated invariant chain, and probably nidogen [7]. All nine exons of
TACSTD1 are represented in the intronless TACSTD2, suggesting that it was formed by retroposition
via an mRNA intermediate. This retroposition preceded the divergence of avian and mammalian
lineages, thus TACSTD genes are more than 300 million years old. Both TACSTD1 and TACSTD2
genes are highly conserved across species [7,8]. Examples of species with TACSTD2 include mice,
chimpanzees, goats, sheep, chickens, and many others according to the Uniprot search [9]. In humans,
the intronless TACSTD2 gene is located on chromosome 1 in 1p32 locus [3].
Human Trop2 is a 35 kDa large transmembrane protein with four N-linked glycosylation
sites, consisting of 323 amino acids [4]. The extracellular domain at N-terminus starts with a
26-amino-acid-long hydrophobic signal peptide [4]. The rest of the extracellular domain is formed
by 248 amino acids and contains 12 cysteine residues, epidermal growth factor (EGF)-like domain,
and thyroglobulin motif. The short transmembrane domain is made of 23 amino acids and the
cytoplasmic tail of 26 amino acids. The cytoplasmic domain contains a motif homologous to the
phosphatidylinositol-4,5-bisphosphate (PIP2)-binding sequence of gelsolin [8], a protein that affects
actin filament organization. In this motif, there is a serine at position 303, which may be phosphorylated
by protein kinase C (PKC) (Figure 1) [10]. This phosphorylation leads to conformational changes
and affects the accessibility of functionally important regions of its cytoplasmic tail [11]. It has been
shown that Trop2 extracellular domains can form dimers [12]. Using molecular dynamic simulations,
Pavšič et al. later demonstrated that the Trop2 dimerization interface extends to the transmembrane
part [11]. However, the effect of dimerization on Trop2 function has not yet been studied in detail.
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Figure 1. The structure of trophoblast cell surface antigen 2 (Trop2) and epithelial cell adhesion
molecule (EpCAM) proteins. The red bands represent N-linked glyc sylation sites at positions 33, 120,
168, and 208 in Trop2 and positions 74, 111, and 198 in EpCAM.
A recent study shows that serine residue at position 322 may also be phosphorylated by PKC [13],
which was predicted earlier for cytoplasmic Trop2 [14]. This phosphorylation is critical for the highly
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motile phenotype of colorectal carcinoma cells [13]. Interestingly, there are no serine residues equivalent
to Trop2 S303 and S322 in EpCAM, suggesting a differences in signaling properties of cytoplasmic
domains of both proteins [11]. Both proteins also differ in the number of glycosylation sites (Figure 1).
Whether these differences in the structure of Trop2 and EpCAM are reflected in their function in health
and disease remains to be determined.
2. Trop2 in Healthy Tissue and Development
Trop2 expression was detected in healthy epithelial cells of many organs including respiratory
tract, cervix, endometrium, fallopian tubes, placenta, seminal vesicles, thymus, vagina, esophagus,
skin, tonsils, cornea, breast, kidney, pancreas, prostate, salivary glands, uterus, lung, stomach,
colorectum, and bile duct epithelium of the liver [15,16]. Besides the above-mentioned organs, Trop2
is also expressed in lungs [17,18], intestines [19], stomach [20], bladder [21], and kidneys [22] during
embryonal and fetal development. Trop2 protein was also detected in granule cells in all layers of the
developing cerebellum, particularly in postmitotic cells, suggesting its function in regulation of cell
migration [23]. In the damaged adult stomach, Trop2 is re-expressed and might be associated with
regeneration processes [20]. The pro-regenerative potential of Trop2-positive cells was also described
in the in vivo model of murine endometrial regeneration [24], and Trop2-positive cortical bone-derived
stem cells hold superior pro-regenerative effect after myocardial infarction in mice [25].
Trop2 is also considered a stem/progenitor cell marker. High expression of this protein has been
found in murine mesenchymal stem cells (mMSC). mMSC from Trop2 KO mice have prolonged cellular
doubling time and impaired differentiation to adipocytes and osteoblasts [26]. Interestingly, a very
recent study found overexpression of Trop2 in the in vitro model of osteoidosis and in the bone surface
of patients with osteomalacia [27]. The authors of this study proposed that increased expression of
Trop2 might act as a stimulator of MSC osteogenic differentiation in an attempt to improve the bone
structure by osteoblasts.
Trop2 also marks the subpopulation of human and murine prostate basal cells with stem cell
characteristics [28]. We have recently shown that Trop2-positive mouse basal prostate stem cells are
enriched in the expression of epithelial-to-mesenchymal transition (EMT) master regulator Slug and
that Slug expression further associates with increased organoid forming capacity of these cells [29].
While Trop2 expression in basal cells does not change during aging, it was found that Trop2 is
significantly upregulated in the “old” prostate luminal cells when compared to adult luminal cells and
that Trop2-positive cells contribute to the vast majority of luminal progenitor activity in old mouse
prostate [30]. Furthermore, expression of Trop2 has been found in murine bladder progenitor cells [21],
intestinal progenitor cells [19], and oval cells [31], which are considered as possible liver stem cells.
In patients with chronic obstructive pulmonary disease (COPD), Trop2 expression is significantly
increased in airway basal cells, acting as the stem/progenitor cells of airway epithelium [32]. In vitro,
Trop2 promotes proliferation and self-renewal of basal cells and induces an EMT-like phenotype and
the release of proinflammatory cytokines. This observation suggests that Trop2 might be crucial in
early airway repair abnormalities and remodeling in COPD patients. Association between Trop2 and
lung cell proliferation was also reported during normal fetal lung growth in sheep and confirmed by
RNA interference in rat fetal lung fibroblasts [17,33]. In kidney, however, Trop2-positive cells did not
proliferate and ectopic expression of Trop2 inhibited cell migration and branching [22].
Trop2 also marks the biliary and liver progenitor cells, discovered after sequencing of EpCAM+
cells from adult human livers, widely considered as hepatic stem cells [34]. Intriguingly, there is a
gradient of Trop2 expression in EpCAM+ cells, and cells with intermediate Trop2 expression exhibit the
highest capacity to form organoids. Subsequent flow cytometric analysis of these organoids revealed
that the populations with high, intermediate, and low or no expression of Trop2 are present again.
Authors suggest that the fraction of cells with intermediate Trop2 expression contains a rare cell
population with the capacity to differentiate into both hepatocytes and cholangiocytes [34].
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Although the results of these studies suggest the active role of Trop2 in the regulation of stem
cell proliferation, migration, and regenerative potential in various tissues, the function of Trop2 in
embryonal development has not been fully understood yet. Trop2 null mice are surprisingly fully
viable, fertile, and lack overt developmental defects, suggesting that Trop2 is not required for mouse
embryonal development and fertility [35]. This is in striking difference to EpCAM null mouse models
that display severe intestinal dysfunction [36–38]. The loss of intestinal tissue integrity observed
in these models corresponds to signs of congenital tufting enteropathy (CTE), a disease caused by
EpCAM mutations in humans [39]. Interestingly, while EpCAM is expressed by intestinal epithelial
cells (IEC) of the developing and adult gut, TROP2 is expressed only in the former [15,19,40]. Recently,
Nakato et al. showed that forced expression of Trop2 in IEC of EpCAM null mice largely prevented
manifestation of CTE. However, the abnormalities in histology and physiology of intestine of these
mice revealed that the function of both proteins is not equivalent [41].
These results suggest that Trop2 is a robust marker of adult stem cell populations, but its function
is most likely dispensable or compensated by other, similar molecule(s). Further studies will be critical
to clarify this issue.
2.1. Germline Mutations in Trop2 (TACSTD2) Gene
Congenital mutations in the human TACSTD2 gene cause a gelatinous drop-like corneal dystrophy
(GDLD) [42]. GDLD is a rare autosomal recessive disease that leads to the development of bilateral
corneal amyloidosis and eventually blindness, with the highest prevalence in Japan. Currently,
there are 32 known mutations in TACSTD2 causing GDLD [43], and four distinct subtypes of GDLD:
band keratopathy type, stromal opacity type, kumquat-like type, and typical mulberry type [44].
Since the same mutation can lead to different phenotypes, GDLD phenotypes also depend on secondary
factors. The most common mutation is the substitution in the codon coding for glutamine at position
118 for a stop codon in the TACSTD2 gene [42]. This substitution leads to the expression of truncated
Trop2 that lacks the transmembrane and intracellular domains and aggregates in the perinuclear
area. Such loss of function of Trop2 in the corneal cells of GDLD patients is responsible for impaired
subcellular localization of tight junction-related proteins, i.e., claudins and occludins, and thickened
basal membrane [45]. In the basal membranes and amyloid deposits, Takaoka et al. discovered the
presence of Lactoferrin, known as a major component of tear fluid. Loss of barrier function of corneal
epithelial cells allows Lactoferrin to pass through the basal membrane to the subepithelial region,
resulting in the formation of amyloid deposits. It is not known why TACSTD2 mutation displays
disease phenotype specifically in the cornea, while other organs covered by stratified epithelia remain
morphologically and functionally unaffected [46].
In the immortalized corneal epithelial cells in vitro, knockout of TACSTD2 and EpCAM genes
leads to the reduced epithelial barrier function and decreased expression and altered subcellular
localization of Claudins 1 and 7 [47]. While the deletion of TACSTD2 affects only localization of Claudin
1, the deletion of both TACSTD2 and EpCAM genes adequately reflects the phenotype of GDLD corneal
epithelial cells. Due to their close phylogenetic relationship, EpCAM is likely able to compensate for
the loss of Trop2 function in vitro. Since EpCAM is not expressed in corneal epithelial cells in vivo,
mutation of the TACSTD2 gene alone sufficiently promotes the development of GDLD [47].
The causal relationship between TACSTD2 gene mutation and GDLD suggests that Trop2 plays a
critical role in the formation of tight junctions in stratified epithelia. Previous studies report the ability
of Trop2 to bind to Claudins 1 and 7 [46]. The exact binding site is yet to be revealed. Presumably,
Trop2 binds to claudins through their AxxxG motifs in transmembrane regions, resembling the
EpCAM-Claudin 7 interaction [48]. The function of such Trop2 interaction with claudins is not entirely
known yet. Nevertheless, a recent study shows that the interaction of Trop2 and Claudin 7 may lead
to the recruitment of Claudin 7 to tight junctions [13]. It is known that Trop2 knockdown leads to
decreased expression and altered subcellular localization of claudins and other tight junction-related
proteins by modulation of their phosphorylation by PKC (Figure 2) [46,49]. The phosphorylation status
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of Trop2 might likely be crucial for proper localization of claudins. Phosphorylation of serine 322
causes decreased co-immunoprecipitation of Trop2 and Claudin 7, which leads to loss of Claudin 7
stability [13].C ncers 2020, 12, x  5 of 27 
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The function of Trop2 in regulation of Claudin 1 and Occludin cellular localization was also
described in hepatocellular carcinoma cells and primary hepatocytes. Mechanistic studies revealed that
Trop2 silencing blocked the phosphorylation of Claudin 1 and Occludin, altered their proper cellular
localization and inhibited hepatitis C virus infection at the level of viral entry into hepatocytes [49].
Recently, membrane-anchored epithelial protease Matriptase was shown to cleave Trop2 and EpCAM
proteins [50–52]. Interestingly, elimination of both proteins was necessary to reduce claudin levels in
keratinocytes confirming the functional redundancy of both protein in regulation of epithelial barrier
function [50].
2.2. Trop2 Signaling and Interaction Network
An early report published more than two decades ago first suggested that Trop2 acts as a
calcium signal transducer by increasing calcium (Ca2+) concentration in the cytosol [53]. The study
also proposed that Trop2 induces the release of calcium from internal reserves, since the signal
is transferred even in the absence of extracellular calcium ions. Such calcium signal transduction
function was assigned to the intracellular domain containing the PIP2-binding sequence [8]. However,
this phenomenon has not been further investigated or independently confirmed. A more detailed,
mechanistic insight into the role of Trop2 as a calcium signal transducer is thus desperately needed.
By contrast, numerous studies reported activation of Akt kinase by Trop2, mostly in cancer cell
lines [54–58] but also in murine mesenchymal stem cells [26]. A large proteomic analysis recently
identified more than 100 signaling molecules modulated by Trop2, with PTEN/PIK3CA/Akt/GSK3ß
being a major activated pathway in cancer cells [59].
Other signaling pathways identified in this large screen that has been confirmed in different
studies include MAPK/ERK [60–62], ErbB [63–65], TGFβ [66], Wnt/β-catenin [66,67], JAK/STAT [68],
integrin signaling [69–72], and adherent and tight junction signaling (Figures 2 and 3). It should also be
noted that the downregulation of Akt and MAPK/ERK pathways by Trop2 were also described [65,73–75],
suggesting that the effect of Trop2 may be cell context-dependent.
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Despite the fact that Trop2 is considered a transmembrane protein, it can also be localized in the
cytoplasm with possible functional consequences [42,65,76]. Cytoplasmic, but not membrane-bound
Trop2, expression positively correlates with phospho-Akt in breast cancer specimens [59]. Stoyanova et al.
reported that Trop2 undergoes regulated intramembrane proteolysis (RIP) [67]. During RIP, the extracellular
domain is cleaved, whereas the intracellular domain is released and enters the nucleus, where it accumulates
in complex with β-catenin that then activates transcription of downstream targets. The extracellular
domain of Trop2 is cleaved by metalloproteinase tumor necrosis factor-α converting enzyme (TACE),
while the intracellular domain (ICD) is cleaved predominantly by presenilin-1 but also by presenilin-2.
Interestingly, Trop2 ICD has been found in human prostate cancer cells but not in benign prostate tissues,
suggesting its role in tumorigenesis [67]. Physical interaction of Trop2 and β-catenin was also observed in
gastric cancer cell lines, where Trop2 is required for β-catenin nuclear accumulation and is associated
with induction of EMT [66]. However, further studies are needed to identify the exact mechanisms that
regulate processing, cellular localization, and posttranslational modifications of Trop2 and to clarify their
effects on the biological function of Trop2.
Besides β-catenin and claudins, only a few Trop2-interacting partners have been identified so far,
mostly affecting their signaling properties (Table 1). Further multi-omics and functional screenings are
therefore necessary to reveal the whole spectrum of Trop2-interacting partners.
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Table 1. List of proteins interacting with Trop2 and cellular functions of these interactions.
Trop2-Interacting Partner Function Reference
β-catenin activation of β-catenin signaling [66,67]
Claudin 1 and 7 facilitation of proper localization [46]
Occludin facilitation of proper localization [49]
α5β1 integrin/Talin complex
relocalization from focal adhesions to leading
edges, rearrangement of focal adhesions sites
through displacement of FAK
[69,70]
IGF-1 inhibition of IGF-1R signaling [73,77]
MDK inhibition of ALK signaling [77]
NRG-1 inhibition of ErbB3 activation [65]
3. Trop2 in Cancer
In the last 40 years, the relation between both TACSTD gene family members, Trop2 and EpCAM,
and cancer has been extensively studied. The functional role of EpCAM during tumorigenesis,
tumor cell dissemination, its value as prognostic marker and therapeutic target has been nicely
reviewed recently [78–81]. Similarly to EpCAM, the overexpression of Trop2 was observed in many
types of carcinomas (Table 2). However, there are specific cancer types in which Trop2 is downregulated
(Table 2). In general, overexpression of Trop2 often correlates with an unfavorable prognosis and
increased risk of metastasis [66,82–87]. Nevertheless, there are exceptions to this trend and in some types
of cancer, the downregulation is correlated with poor prognosis instead [88] (Table 2). Interestingly,
prognostic value of Trop2 may also depend on its cellular localization within tumors. Ambrogi et al.
reported that the membranous Trop2 is associated with worse survival, while the Trop2 intracellular
retention is associated with better survival and less frequent disease relapse in breast cancer patients [89].
The importance of different Trop2 forms and cellular localizations in carcinoma prognosis, however,
has to be further established.
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Table 2. Table list alterations in Trop2 expression and effects on prognosis in different types of carcinomas.
Trop2 Overexpression
Type of Carcinoma Detection Method Number of Subjects Protein Location Prognosis Reference
gastric
IHC 104 membrane
decreased overall and disease-free survival
(in patients with intestinal-type carcinoma
and lymph-node-positive patients)
[85]
IHC 830 membrane, cytoplasm decreased overall and disease-free survival [90]
qRT-PCR 41 pairs - -
IHC 330 membrane, cytoplasm decreased overall survival (in patients withTrop2+/vimentin+ expression) [66]
IHC 844 membrane N/A [91]
ICC 192 - -
thyroid
IHC 124 membrane, cytoplasm -
[61]qRT-PCR 18 pairs - -
RNA seq 59 pairs - -
papillary thyroid
ICC 60 - - [92]
IHC 94 membrane, cytoplasm -
IHC 433 membrane - [93]
IHC 468 membrane - [94]
colorectal
IHC 620 - decreased overall survival and increaseddisease recurrence [95]
IHC 34 - - [96]
qRT-PCR 74 pairs - decreased overall survival
non-small cell lung
IHC 104 membrane, nucleus,cytoplasm
decreased overall survival (in patients with
adenocarcinoma) [97]
IHC 334 membrane decreased overall survival (in patients withadenocarcinoma) [98]
IHC 164 membrane better overall and disease-free survival (inpatients with adenocarcinoma) [74]
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Table 2. Cont.
Trop2 Overexpression
Type of Carcinoma Detection Method Number of Subjects Protein Location Prognosis Reference
lung adenocarcinoma
IHC 130 membrane, cytoplasm decreased overall survival (in patients withnon-lepidic type tumors) [76]
IHC 68 membrane, cytoplasm decreased overall survival [99]
qRT-PCR 20 pairs - -
breast
IHC 702 membrane, cytoplasm
decreased overall survival associated with
membrane Trop2, intracellular Trop2
associated with better overall survival and
disease recurrence
[89]
IHC 354 decreased overall survival (in patients withTrop2+/E-cadherin- expression) [87]
qRT-PCR 20 pairs - -
ductal breast
IHC 152 membrane decreased overall survival [100]
qRTPCR 15 pairs - -
pancreatic IHC 207 membrane
decreased overall survival and shortened
progression-free survival in patients who
underwent surgery with curative intent
[82]
ovarian
IHC 117 membrane, cytoplasm decreased overall and progression-freesurvival [101]
qRT-PCR 128 - N/A
IHC 55 membrane - [102]
IHC 90 membrane, cytoplasm - [103]
prostate
IHC 339 membrane, cytoplasm - [84]
IHC 148 membrane - [69]
bladder IHC 40 membrane, cytoplasm - [104]
gallbladder IHC 93 membrane, cytoplasm decreased overall survival [105]
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Table 2. Cont.
Trop2 Overexpression
Type of Carcinoma Detection Method Number of Subjects Protein Location Prognosis Reference
gallbladder
IHC 105 membrane, cytoplasm decreased overall survival
[56]qRT-PCR 56 - -
WB 10 - -
cervical
IHC 160 membrane decreased overall and progression-freesurvival [62]
IHC 13 membrane - [106]
IHC 147 membrane, cytoplasm - [107]
uterine serous
papillary
IHC 28 membrane - [108]
IHC 104 membrane, cytoplasm - [109]
uterine and ovarian
carcinosarcomas IHC 10 membrane, cytoplasm - [110]
endometrial
IHC 163 membrane - [111]
IHC 118 membrane decreased disease-free survival [112]
nasopharyngeal qRT-PCR 37 - - [54]
IHC 58 membrane, cytoplasm decreased overall and disease-free survival [113]
hilar
cholangiocarcinoma
IHC 70 membrane decreased overall survival [86]
qRT-PCR 56 pairs - -
oral squamous cell
IHC 90 membrane decreased overall survival [83]
IHC 443 membrane, cytoplasm decreased overall and disease-free survival [114]
qRT-PCR 93 - -
IHC 320 membrane, cytoplasm decreased overall survival (in patients withTrop2+/P16- expression) [115]
IHC 108 cytoplasm decreased overall survival [116]
esophageal squamous
cell IHC 55 membrane, cytoplasm - [117]
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Table 2. Cont.
Trop2 Overexpression
Type of Carcinoma Detection Method Number of Subjects Protein Location Prognosis Reference
head-and-neck
squamous cell IHC 42 membrane decreased overall and disease-free survival [118]
laryngeal squamous
cell
IHC 137 membrane, cytoplasm decreased overall and disease-free survival [119]
qRT-PCR 15 pairs - -
Trop2 Downregulation
Type of Carcinoma Detection Method Number of Subjects Protein Location Prognosis Reference
liver fluke-associated
cholangiocarcinoma IHC 85 membrane, cytoplasm N/A [75]
lung adenocarcinoma IHC 55 pairs membrane - [73]
LOH analysis 119 - -
hepatocellular qRT-PCR 205 pairs - decreased overall survival [88]
RNA seq 3 pairs - -
squamous cell
carcinoma of cervix IHC 79 membrane, cytoplasm - [64]
squamous cell
carcinoma of head and
neck




IHC 6 membrane, cytoplasm -
Only patient-related data from clinical studies are included. IHC stands for immunohistochemistry, ICC stands for immunocytochemistry, LOH stands for loss of heterozygosity, WB stands
for Western blot, qRT-PCR stands for quantitative reverse-transcription PCR, N/A stands for no association with prognosis, - means association with prognosis was not studied.
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High expression of Trop2 was also found in tumors of non-epithelial origin, such as melanomas [120],
extranodal nasal NK/T cell lymphoma [121], gliomas and glioblastomas [68,122], and osteosarcomas [55].
Trop2 was also found to be overexpressed in pituitary adenomas [123].
3.1. Regulation of Trop2 Expression in Cancer
Although Trop2 is frequently overexpressed during tumorigenesis, genetic analyses revealed that
point mutations and copy number variations in TACSTD2 gene are rather rare in human tumors [16,124];
COSMIC database [124] accessed on 14 July 2020; Cancer Genome Atlas (https://www.cancer.gov/tcga)
accessed on 14 July 2020). These data suggest that the overexpression of Trop2 in cancer does not
arise from structural alterations of the gene itself but are rather results from deregulation at the
transcriptional and posttranscriptional level. In an attempt to describe the Trop2-regulatory pathways
in cancers, Guerra et al. identified a network of transcription factors that modulate Trop2 expression.
This network includes TP63/TP53, ERG, GRHL1/Get-1, HNF1A/TCF-1, SPI1/PU.1, WT1, GLIS2, AIRE,
FOXM1, and FOXP3 [125]. Moreover, subsequent studies identified the Trop2-regulatory function of
CREB in breast cancer [126].
Signaling pathways that regulate Trop2 expression includes cyclooxygenase-2 and tumor necrosis
factor-α in colon carcinoma cells [127,128], PTEN and lipoxygenase in prostate cells ([129,130], TGF-β
in Langerhans cells [131], and fibroblast growth factor in embryonic lungs [132]. These pathways
are often deregulated during tumorigenesis and may be, therefore, at least partially responsible
for modulation of Trop2 expression in malignant cells. Interestingly, Trop2 expression can be as
well induced by mechanical forces [17]. As mechanical stress arises during tumorigenesis [133],
mechanotransduction could also represent an important factor in Trop2 regulation. This, however,
remains to be proven experimentally.
Epigenetic factors were identified as important modulators of Trop2 expression in cancers, too.
Hao et al. recently described circRNA—miR-488-3p—Trop2 regulatory loop that released Trop2
epigenetic silencing in head-and-neck squamous cell carcinoma cell lines [118]. Other miRNAs that
target Trop2 were also identified in head-and-neck carcinoma [134] and urothelial bladder cancer [135].
Furthermore, we and others showed that Trop2 expression is regulated by methylation of TACSTD2
gene promoter in various cancer cells [73,75,88,136,137]. Importantly, Lin et al. found hypermethylation
of TACSTD2 gene promoter in lung adenocarcinoma tissues and cell lines explaining low expression of
Trop2 in this type of cancer [73]. Complex data from single-cell analyses may uncover the importance
of all these factors as sources of Trop2 heterogeneity in various cancers.
3.2. Multiple Functions of Trop2 in Cancer
3.2.1. Trop2 and EMT
Decreased adhesion and increased motility are important steps for successful metastatic
colonization of secondary organs. In order to acquire the phenotype of mesenchymal cells with
enhanced migratory capacity and invasiveness, polarized epithelial cells undergo an evolutionarily
conserved transcriptional program known as EMT [138]. EMT is associated with a functional
decrease in epithelial markers such as E-cadherin and upregulation of mesenchymal markers such
as Vimentin, N-cadherin, and Fibronectin. Both EMT and its inversed process, known as the
mesenchymal-to-epithelial transition (MET), are essential for the formation of metastases [139]. EMT is
also hypothesized as one of the mechanisms leading to the generation of cancer cells with stem cell
phenotype [139].
Our recent study found that the membrane expression of Trop2 positively correlates with
E-cadherin expression and negatively with the mesenchymal gene signature in a wide panel of human
and murine breast and prostate cancer cell lines, as well as human tumors [137]. Our findings suggest
that in breast and prostate cancers, the surface Trop2 expression associates with the epithelial phenotype.
Furthermore, we have shown that the Trop2 expression is suppressed either epigenetically through the
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DNA hypermethylation or EMT transcription factors, i.e., ZEB1 during EMT [137]. Similarly, the protein
level of E-cadherin is significantly decreased in the absence of mTrop2 (murine Trop2) in immortalized
murine keratinocytes [35]. The same study also shows that Ras-transformed keratinocytes deficient
for Trop2 preferentially pass through EMT. In mTrop2-positive cells, the mTrop2 expression is lost
during transformation associated with mesenchymal transdifferentiation. Moreover, TACSTD2 mRNA
levels are decreased in a subset of primary head-and-neck squamous cell carcinomas with features of
EMT [35].
However, it should be noted that the association between Trop2 and mesenchymal phenotype
was reported previously in other cancer types, suggesting that the link between Trop2 and EMT may
be cancer type/cell context dependent. Li et al. described that the downregulation of Trop2 reduces the
expression of Vimentin and upregulates E-cadherin in gallbladder cancer both in vitro and in vivo,
while Trop2 overexpression has the opposite effects [56]. In this model, Trop2 is also involved in the
PI3K/Akt pathway, since the downregulation of Trop2 inhibits Akt phosphorylation and increases the
expression of PTEN, a negative regulator of Akt activity [56]. PI3K/Akt pathway is well-known to
induce EMT [140]. The findings by Li et al. are supported by previously published studies, which have
also found that high expression of Trop2 is associated with reduced expression of E-cadherin in cervical
cancer cell lines [62], gallbladder cancer [105], and gastric cancer cell lines [66]. In nasopharyngeal
carcinoma cells, Trop2 promotes EMT through the activation of NF-κB [54]. Inactivation of the NF-κB
pathway in these cells attenuates Trop2-induced invasion and EMT. Overexpression of Trop2 leads to an
increased N-cadherin, Vimentin, and Twist as well as decreased E-cadherin, while Trop2 downregulation
has the opposite effect. In gastric cancer cell lines, Trop2 binds to β-catenin and promotes its nuclear
translocation and accumulation, increasing its transcription activity and contributing to the EMT [66].
Inhibition of EMT by Trop2 silencing has been observed recently in endometrial cancer cells as well [57].
Overall, the results of studies linking Trop2 with EMT are contradictory, and the precise role
and significance of Trop2 in this process remain to be elucidated. We believe that understanding the
functional consequences of EMT-related intratumoral heterogeneity in Trop2 expression is of great
importance, as it may significantly affect the response to therapies targeting Trop2-expressing cells.
3.2.2. Trop2 and Cell Proliferation
In many tumor types, Trop2 stimulates proliferation and cellular growth. In cervical cancer cells,
Trop2 promotes proliferation by regulating the ERK signaling pathway [62]. Down-regulation of Trop2
results in decreased cyclin D1, cyclin E, cyclin-dependent kinases (CDK)2, and CDK4 expression,
as well as in an increased p27, an inhibitor of CDKs. Similarly, in human bladder cancer cell lines,
Trop2 overexpression suppresses the protein levels of p27 and induces expression of cyclin E1 [141].
Interestingly, Trop2 overexpression combined with curcumin treatment partially abrogates these effects,
and it seems that curcumin exhibits some of its anti-tumor activity by regulating Trop2 expression.
In murine pancreas adenocarcinoma cell line, mTrop2 also increases levels of phosphorylated ERK1/2,
which leads to an increase in proliferation activity in low serum conditions [60].
Overexpression of ectopic Trop2 in a large panel of immortalized and transformed cell lines
stimulates cell growth, associated with higher proportions of cells in the S phase of the cell cycle [16].
In the same study, Trop2 potentiates tumor growth in vivo proportionally to the Trop2 expression
levels. Trop2 also enhances the capacity of colon cancer cells for anchorage-independent growth [142].
In glioblastoma cells, Trop2 promotes growth and dissemination by the activation of the JAK2/STAT3
signaling pathway [68] and attenuates the expression of molecules downstream of this signaling
pathway such as cyclin D1, survivin, matrix metalloproteinase 2 (MMP2), and vascular endothelial
factor (VEGF). Furthermore, knockdown of Trop2 in glioblastoma cells leads to the inhibition of
JAK/STAT phosphorylation.
On the other hand, the ability of Trop2 to suppress cell proliferation was also reported. In lung
adenocarcinoma, Trop2 expression is often downregulated [73]. While the increased Trop2 expression
in one lung cancer cell line leads to the suppression of cell proliferation, the silencing of Trop2 in
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another cell line promotes it. Trop2 knockdown also significantly stimulates cell proliferation and
migration in cholangiocarcinoma cell lines and is associated with increased ERK phosphorylation [75].
Furthermore, knockdown of Trop2 in the cervical cancer cells promotes cell proliferation, migration,
and invasion capabilities in vitro and enhances tumor growth capability in vivo [77]. In the MCF7
breast cancer cell line, knockdown of Trop2 slightly increases proliferation when compared to control
cells [143]. The above-described findings suggest that the role of Trop2 in regulating proliferation is a
complex, cell type-, and organ-specific phenomenon.
3.2.3. Trop2 and Cell Adhesion and Migration
The ability of Trop2 to promote migration and invasion of cancer cells was described in several
types of tumors, but different mechanisms of Trop2 involvement were suggested. In prostate cancer
cells, Trop2 was shown to promote cell motility by inhibition of cell adhesion to the extracellular matrix
glycoprotein Fibronectin [71]. This is achieved by a complex mechanism comprising direct interaction
of Trop2 with α5β1 Integrin complex and Talin, their relocalization from focal adhesions to the leading
edges, RACK1 translocation to cell membrane, Src and FAK activation resulting in a faster turnover of
adhesive structures and destabilization of the α5β1Integrin complex bond to Fibronectin (Figure 2) [71].
Interestingly, Trop2-positive exosomes were found to promote migration of Trop2-negative prostate
cancer cells on Fibronectin by a yet unknown mechanism [69]. In thyroid cancer cells, Trop2 stimulates
the expression of MMP2 through an MAPK ERK/JNK signaling pathway and enhances the invasion of
these cells [61]. As briefly mentioned above, the migratory capacity of colorectal carcinoma cells is
dependent on phosphorylation of serine 322 of Trop2, resulting in Claudin 7 relocalization. Blocking
of this phosphorylation site decreases such migration, and cells expressing phospho-mimetic Trop2
exhibit higher migratory capacity [13].
3.2.4. Trop2 and Drug Resistance
It is not surprising that Trop2 appears to have a dual function in the regulation of cancer cell
survival and drug resistance as well. Overexpression of Trop2 in cervical cancer cell lines inhibits
apoptosis by increasing the expression of Bcl-2 and decreasing the expression of Bax [62]. Similarly,
the downregulation of Trop2 in ovarian carcinoma cells decreases Bcl-2 and increases Bax expression [144].
In bladder cancer cell lines, transient silencing of Trop2 leads to an increased apoptosis and sensitizes
cells to curcumin treatment, while Trop2 overexpression reduces the frequency of apoptotic cells and
abrogates curcumin-induced cell death [141]. Inhibition of Trop2 significantly increases apoptosis of
non-small cell lung carcinoma (NSCLC) cells [99] and overexpression of Trop2 decreases apoptosis in oral
squamous cell carcinoma cell lines [58]. In prostate cancer xenografts, Trop2 was upregulated in relapsed
tumors after flutamide and docetaxel treatment and Trop2 enhanced recovery of androgen-sensitive,
but not androgen-resistant cells, after exposure to docetaxel [145]. Silencing Trop2 using shRNA resulted
in increased sensitivity to cisplatin in lung and cisplatin/5-fluorouracil in gastric cancer cells in vitro
and in vivo [146,147].
In contrast to these findings, Trop2-overexpressing cervical cancer cells are more sensitive to
cisplatin-induced apoptosis, while such cells with silenced Trop2 expression are more resistant [77].
Similarly, Trop2 silencing reduced the sensitivity of transformed keratinocytes to gemcitabine [64].
As expected, modulation of Trop2 signaling through the epidermal growth factor receptor 3
(ErbB3), insulin-like growth factor 1 receptor (IGF-1R), and Akt pathways (see Chapter 2.2 and 3.2.6)
reflects the observed association between Trop2 expression and resistance to EGFR inhibitor gefinitib
in head-and-neck squamous cell carcinoma [148], altered response of Trop2-overexpressing cells to
IGF-1R inhibitor AG-1024 in HeLa cells [77], and reduced response of Trop2 shRNA transfected breast
cancer cells to allosteric Akt inhibitors [59].
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3.2.5. Other Functions in Cancer
Furthermore, several studies imply a possible role of Trop2 in angiogenesis. In glioblastoma cells,
Trop2 overexpression upregulates VEGF levels, and accordingly, its downregulation leads to decreased
VEGF expression [68]. VEGF is a potent angiogenic factor that promotes the growth of blood vessels,
which allows tumor growth and dissemination. In gliomas [122] and hilar cholangiocarcinomas [86],
Trop2 expression positively correlates with microvessel density.
It was also found that in Trop2 and seven other genes, encoding barrier molecules are highly
expressed in a subset of metastatic melanomas and ovarian carcinomas, and their expression is
associated with a lack of immune gene signatures and worse prognosis [120]. This subset of tumors
with high expression of barrier molecules is usually not infiltrated by T cells. Such T cell infiltration of
tumors is associated with an improved prognosis in different types of cancer [120].
A recent study shows that Trop2 induces neuroendocrine phenotype of prostate cancer,
and overexpression of Trop2 leads to the significant increase in Poly(ADP-Ribose) polymerase 1
(PARP1) [84], an enzyme critical for DNA repair regulation, replication, transcription, and chromatin
remodeling [149]. Trop2 overexpression results in increased DNA replication and accumulation of
DNA damage even though PARP1 and other DNA repair proteins are upregulated in these cells [84].
It was proposed that Trop2 regulates PARP1 through the upregulation of c-MYC, but this remains to be
elucidated. In vivo, inhibition of PARP1 leads to the reversion of neuroendocrine phenotype and a
decrease in tumor growth and metastasis.
3.2.6. Trop2 as Tumor Suppressor (Until It Is Not)
It is broadly accepted that in a wide spectrum of cancers high Trop2 expression promotes tumor
growth [16] and positively correlates with metastasis and poor prognosis, suggesting that Trop2 acts as
a putative oncogene. However, opposite findings were reported, showing that in specific cases Trop2
acts as a tumor suppressor.
Low expression of Trop2 in lung adenocarcinomas was attributed to the DNA hypermethylation
in the TACSTD2 promoter region or by the loss of heterozygosity [73]. In lung adenocarcinoma cell
lines, Trop2 interacts with insulin-like growth factor 1 (IGF-1) and prevents its binding to the IGF-1R.
This further blocks the Akt and ERK kinases activation, β-catenin, and Slug expression and reduces
cell proliferation. Accordingly, loss of Trop2 expression results in the stimulation of cell proliferation
and tumor growth in vivo. A study by Pak et al. shows that Trop2 overexpression is associated with
better survival in patients with NSCLC [74]. However, another study reported an association between
high Trop2 expression, metastasis, and poor prognosis in another NSCLC cohort. Furthermore, Trop2
overexpression in lung adenocarcinoma cell lines stimulates cell proliferation, migration, and invasion,
whereas knockdown of Trop2 induced apoptosis [99].
Trop2 also exhibits tumor suppressive functions in cervical cancer cells, where it similarly
inhibits the activation of IGF-1R and anaplastic lymphoma kinase (ALK), possibly through binding
to their ligands IGF-1 and midkine (MDK) [77]. Another such example is the reduced or completely
lost expression of Trop2 in the mesenchymal subtype of squamous head-and-neck carcinoma [35].
Decreased Trop2 expression leads to increased phosphorylation of the ErbB3 receptor, also known
as HER3, in this cancer type. As Trop2 interacts with neuregulin-1 (NRG-1), a ligand of ErbB3,
inactivation of Trop2 increases the concentration of NRG-1 on the cell surface, which is then cleaved
by metalloproteinase TACE [65]. The released extracellular domain of NRG-1 then activates ErbB3,
promoting cell proliferation and tumor growth (Figure 2). Squamous cell carcinomas are characterized
by a gradual loss of Trop2 during progression, inversely proportional to ErbB3 [64]. Interestingly,
resistance to anti-ErbB3 treatment in head-and-neck squamous cell carcinoma is associated with
increased Trop2 protein expression [63]. Co-treatment with both anti-ErbB3 and anti-Trop2 antibodies
leads to a greater anti-tumor response than either antibody alone.
Moreover, decreased expression of Trop2 has been found in liver fluke-associated
cholangiocarcinomas [75] and hepatocellular carcinomas [49,88]. Trop2 downregulation is in both cases
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epigenetically controlled by hypermethylation of TACSTD2 promoter. Low Trop2 expression associates
with poor overall survival, invasion, and poor differentiation in hepatocellular carcinomas [88], but not
in cholangiocarcinomas [75]. Similarly, our study shows that in lymph-node-positive breast cancer and
prostate cancer patients, low expression of TACSTD2 mRNA associates with worse prognosis [137].
Interestingly, exposure of mTrop2−/−Arf−/− mice to 7, 12-dimethylbenzanthracene and
12-O-tetradecanoylphorbol-13-acetate (DMBA-TPA) results in the formation of skin carcinomas,
whereas none of the mTrop2+/+:Arf−/−mice developed tumors [35]. Immortalized keratinocytes derived
from mTrop2−/−Arf−/− exhibited enhanced proliferative and migratory capacity when compared to
mTrop2+/+Arf−/−.
It again seems that there is more than one possible interpretation of such conflicting findings.
The precise role of Trop2 likely depends on the wider genetic context of a particular cancer
cell. A phenomenon commonly known as non-oncogene addiction may further explain these
contradictions [5]. In this situation, tumor cells are hyper-dependent upon non-oncogenic genes for
survival within the physiologically stressful microenvironment. Moreover, the results of the reviewed
studies also suggest the possibility that the role of Trop2 changes gradually, from early tumorigenesis,
where it acts as a tumor suppressor, to later stages, where its reactivation induces metastasis and
associates with the worse prognosis. Unlike the “genetic context hypothesis”, this gradual increase
in Trop2 explains its widespread expression in cancer, regardless of its dual role in many related
processes. This speculation, however, requires further testing in relevant systems. Another question
that remains yet unanswered is the impact of various Trop2 forms and their subcellular localization
on cancer cell behavior. This was addressed by only a very limited number of studies, although the
signaling properties, oncogenic or tumor suppressive role, and the prognostic value of these different
forms in tumors deserve further thorough investigation.
3.3. Trop2 in Cancer Therapy
Due to its frequent overexpression in tumors, Trop2 seems to be an exceptionally promising
candidate for immunotherapeutic strategies. The murine monoclonal antibody RS7-3G11 has
been raised against human NSCLC cells [150]. This antibody showed pan-carcinoma specificity
including breast, colon, lung, renal, stomach, bladder, breast, ovary, uterus, and prostate [151].
Subsequently, Trop2 was identified as its antigen [10]. This clone promoted antibody-dependent
cell-mediated cytotoxicity in vitro in ovarian [102], cervical [106], uterine [108], and endometrial
carcinoma cells [111]. Radiolabeled RS7 was efficient in targeting and killing human cancer xenografts
in immunocompromised mice [152–154]. This antibody was rapidly internalized from the surface
of cancer cells [151,155], providing an opportunity for targeted delivery of cytotoxic compounds
to Trop2-expressing cancers. This approach was tested with mutant Rap toxin conjugated with a
humanized RS7 (hRS7) antibody, and these experimental conjugates suppressed the growth of epithelial
cancer cell lines and xenografts [156,157].
The antibody–drug conjugate IMMU-132, also known as sacituzumab govitecan, was formed by
linking the hRS7 antibody to topoisomerase I inhibitor SN-38 [158]. SN-38 is an active metabolite of
irinotecan, the chemotherapeutic agent often used for clinical management of colorectal carcinomas [159].
The development of this conjugate and the results of preclinical and clinical studies in various cancer
types have been reviewed recently [160,161]. These studies demonstrated a significant clinical response,
good pharmacokinetic profile, no immunogenicity, and manageable toxicity of sacituzumab govitecan
in heavily pretreated metastatic cancers, especially in triple-negative breast cancer (TNBC) [162–171].
Based on these results, sacituzumab govitecan received the Breakthrough Therapy Designation from
the U.S. Food and Drug Administration (FDA) in 2016 [172], and during the preparation of this review,
the FDA accelerated its approval for the treatment of adult patients with metastatic TNBC who have
received at least two prior therapies for metastatic disease [173].
Unfortunately, clinical studies have not provided conclusive evidence that Trop2 levels predicted
responsiveness to sacituzumab govitecan, possibly because of the high frequency of strong positive
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specimens [161]. Further clinical studies are therefore needed to select patients for this type of therapy,
including those with less advanced disease, to investigate effective therapeutic combinations and to find
suitable predictive markers. Clinical trials currently testing sacituzumab govitecan are summarized in
Table 3.
Table 3. List of clinical trials that test the efficacy of sacituzumab govitecan alone or in combined settings.
ClinicalTrials.gov
Identifier Disease Combined Therapy Phase
NCT03964727 Metastatic NSCLC, head-and-neck squamouscell carcinoma, endometrial cancer - 2
NCT03725761 Metastatic castration-resistant prostate cancer - 2
NCT04230109 Invasive localized TNBC - 2
NCT01631552 Advanced epithelial cancers - 1/2
NCT03547973 Metastatic urothelial carcinoma Pembrolizumab 2
NCT03901339 HR+/HER2- metastatic breast cancer - 3
NCT02574455 Refractory/relapsed metastatic TNBC - 3
NCT04039230 Metastatic breast cancer Talazoparib 1/2
NCT03995706 Glioblastoma, metastatic brain tumors - early 1
NCT03992131 Metastatic solid tumors—ovarian cancer,TNBC, urothelial carcinoma Rucaparib 1/2
NCT04251416 Persistent of recurrent endometrial carcinoma - 2
NCT04319198 Metastatic solid tumor - 3
NCT03424005 Metastatic or inoperable locally advancedTNBC Atezolizumab 1/2
NCT04454437 Metastatic TNBC - 2
NCT04468061 Metastatic TNBC Pembrolizumab 2
NCT04448886 Metastatic HR+/HER2- breast cancer Pembrolizumab 2
NCT03337698 Metastatic NSCLC Atezolizumab 1/2
NCT04559230 Glioblastoma - 2
NCT04527991 Metastatic or locally advanced unresectableurothelial cancer - 3
The database was accessed on 6 October 2020.
Besides sacituzumab govitecan, several other Trop2-targeting immunotherapies are being
developed and tested. A hRS7 conjugate with auristatin derivative, a microtubule polymerization
inhibitor, was tested in preclinical studies and phase I clinical study in solid metastatic tumors [174,175].
However, severe adverse effects and only modest anti-tumor activity were observed [174].
In 2014, a human Fab antibody against the Trop2 extracellular domain was isolated from a phage
library [176]. Trop2 Fab antibody itself induces apoptosis and inhibits proliferation and migration
of breast carcinoma cells in vitro, and the growth of breast cancer xenografts in vivo. It also leads
to elevated Bax expression and reduced Bcl-2 expression, both in vitro and in vivo. Two years
later, Mao et al. prepared Trop2Fab-DOX conjugate that specifically binds to pancreatic cancer cells
expressing Trop2, inhibiting their proliferation and migration in vitro and reducing the tumor growth
in vivo [177].
Further development of Trop2-targeting therapies involves nanoparticles conjugated with
anti-Trop2 antibody [178]. These nanoparticles consist of carboxymethyl dextran derivatives with
bioreducible disulfide bonds loaded with doxorubicin. After binding to Trop2, nanoparticles enter
the cells by endocytosis where doxorubicin is released. In vitro experiments show that nanoparticles
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are selectively taken up by Trop2-expressing TNBC cell lines and exhibit higher toxicity than control
nanoparticles lacking the disulfide bond or anti-Trop2 antibody.
Other approaches tested includes Trop2 bispecific antibodies that target T cells to tumors [179],
immunization with virus-like particles incorporating Trop2 [180,181] and anti-Trop2-based
photothermal therapy [182].
4. Conclusions
Studies in the past decade showed that Trop2 is a critical regulator of multiple essential processes
involved in carcinogenesis and cancer progression. Even though initially identified as an oncogene [142],
it turns out that the role of Trop2 is not that straightforward. Recent data suggest that Trop2 acts both
as an oncogene and tumor suppressor. The exact reason for these opposite observations remains to be
determined. The therapeutic potential of Trop2 has been pursued in several successful clinical trials.
Independently of its function, the simple fact that Trop2 is overexpressed in most cancers, while healthy
tissues express it only sporadically, making it an incredibly promising target for cancer-specific delivery
of cytotoxic agents. Such a strategy is already utilized by several drugs, while others are being
developed. However, it should be noted that Trop2-targeting therapy may spare the Trop2-negative
cells within heterogeneous tumors. Further pre-clinical and clinical studies are necessary to clarify the
fate and properties of this cell population in response and resistance to Trop2-targeting therapies.
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